Enlitic slashed its net operating cash outflow by 76% in Q2 FY26 and secured binding commitments for a A$15 million conditional placement alongside convertible note conversions, positioning the company with a pro forma cash balance of about A$18 million and a debt-free balance sheet.
- Net operating cash outflow reduced to US$0.7m in Q2 FY26
- 17 new client agreements signed, total contract value ~US$1.0m
- Conditional A$15m placement and convertible note conversion secured
- Pro forma cash balance expected at ~A$18m, debt-free post transactions
- Focus on expanding Ensight subscriptions and OEM channel growth
Sharp Reduction in Cash Burn Signals Improved Financial Discipline
Enlitic (ASX:ENL) reported a dramatic 76% reduction in net operating cash outflow to US$0.7 million for the June quarter, down from US$2.9 million in the previous period. This improvement was driven by a significant jump in cash receipts to US$2.3 million, reflecting collections on contracts signed earlier, alongside disciplined cost management that lowered operating expenses to US$3.0 million.
While the company’s cash balance at quarter-end stood at US$2.05 million, this figure predates the post-quarter binding commitments for a conditional placement of approximately A$15 million and the conversion of existing convertible notes. Together, these transactions are expected to deliver a pro forma cash position of around A$18 million and clear the company’s debt, providing a runway exceeding 12 months.
Sustained Contract Wins with Focus on Recurring Revenue
Enlitic maintained commercial momentum by signing 17 new client agreements during Q2 FY26, matching the prior quarter’s volume but skewed toward smaller migration contracts with a total contract value near US$1.0 million. Notable deals included a three-year Ensight subscription with Lumus Imaging in Australia valued at US$248,000, and a similar subscription with Radiology Consultants of Iowa worth US$143,000.
The company’s strategy to convert its installed base through OEM integrations appears to be gaining traction. Enlitic now has eight signed OEM agreements and six live integrations, with nearly 1,000 sites onboarded globally. This OEM channel is designed to compress the traditional enterprise sales cycle from 18–24 months to approximately six months, accelerating revenue conversion from pipeline opportunities.
Operational Highlights Include Key Go-Lives and Platform Validation
Enlitic’s Ensight platform went live at New Zealand’s largest private radiology provider, RHCNZ Medical Imaging Group, marking a significant milestone in validating its Intelerad integration in a live production environment. This deployment, along with the first Australian Ensight subscription with Lumus Imaging, underscores the company’s land-and-expand commercial model focused on recurring subscription revenue.
CEO Michael Sistenich highlighted that with shareholder approvals secured for the capital raising and convertible note conversions, the company is well-positioned to advance its strategy. The focus for the remainder of the year is on delivering scheduled customer go-lives, expanding Ensight deployment, and building recurring revenue streams through OEM and partner channels.
Capital Raising and Capital Structure Simplification
Post-quarter, Enlitic secured shareholder approval for a conditional placement at A$0.004 per CDI, a security purchase plan targeting up to A$1 million, and a 10:1 share consolidation. The convertible notes conversion into CDIs aims to simplify the capital structure and eliminate debt. Completion of these transactions remains subject to final conditions but is expected imminently, with settlement targeted for early August.
The capital raised is earmarked to fund commercialisation efforts, sales and marketing scale-up, working capital, and to support the balance sheet as the company moves toward operational cash flow break-even. While the timing of contract revenue recognition depends on customer schedules, the strengthened financial position provides a solid foundation for growth.
Bottom Line?
Enlitic’s sharp cash burn reduction and near-term capital injection set the stage for scaling its SaaS platform, though execution risks remain tied to customer deployments and revenue timing.
Questions in the middle?
- Will Enlitic’s OEM integrations accelerate the sales cycle as projected?
- How soon can the company achieve operational cash flow break-even given current contract schedules?
- What impact will the 10:1 share consolidation have on investor sentiment and liquidity?